Verapamil Hydrochloride BP tablets for prescribed cardiovascular indications. The supplied product text describes separate 40 mg prolonged-release and 80 mg film-coated presentations.
40 mg: Verapamil Hydrochloride BP 40 mg, described as prolonged-release in supplied text; release designation requires verification against registered product specifications.
80 mg: Each film-coated tablet contains Verapamil Hydrochloride BP 80 mg; prolonged-release is not confirmed for this strength.
Therapeutic class: Non-dihydropyridine calcium-channel blocker / Cardiovascular agent.
Manufacturer named in brief: Healthy Life Pharma Pvt. Ltd. Exporter named: Healthy Inc. Certifications require documentary verification.
B2B enquiries: +91 7710003340
Verapamil Hydrochloride Tablets BP PR/ Film-Coated is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Verapamil hydrochloride is a non-dihydropyridine calcium-channel blocker used for certain cardiovascular conditions, including hypertension, angina and selected supraventricular arrhythmias, depending on the approved formulation and jurisdiction.
The supplied labels describe 40 mg prolonged-release and 80 mg film-coated tablets. These should not be treated as interchangeable formulations. In particular, a 40 mg prolonged-release presentation is unusual compared with more common higher-strength modified-release products; the release claim must be confirmed with approved labeling and dissolution data before marketing.
Healthy Life Pharma Pvt. Ltd. and Healthy Inc are named as manufacturer and exporter in the supplied brief; certifications and manufacturing capabilities require verification.
| Product name | Verapamil Hydrochloride Tablets BP |
|---|---|
| Active ingredient | Verapamil Hydrochloride BP |
| Presentation A | 40 mg tablet, described as prolonged-release (PR); verify registered release profile |
| Presentation B | 80 mg film-coated tablet; release mechanism not specified on supplied label |
| Standard | BP as stated in supplied product text |
| Therapeutic class | Non-dihydropyridine calcium-channel blocker |
| Other strengths | 120 mg and 240 mg mentioned in promotional text, not confirmed by supplied labels |
| Packaging and shelf life | To be confirmed from approved registration and stability data |
Verapamil tablet manufacturing requires control of identity, content uniformity, compression, coating and dissolution. A prolonged-release product additionally requires validated release-control technology and a formulation-specific multipoint dissolution profile.
Hydrophilic matrix systems are one possible modified-release approach, but the exact technology and claimed 24-hour release of the supplied 40 mg product cannot be assumed without approved manufacturing records and clinical/pharmacokinetic support. The 80 mg film-coated product must be assessed independently.
Do not assume a 24-hour release profile or fixed dissolution limits from strength alone.
Verapamil inhibits L-type calcium channels in cardiac and vascular tissues. It reduces cardiac conduction through the AV node and relaxes arterial smooth muscle.
Indications and dosing differ between immediate-release and prolonged-release products. Verapamil is not suitable for every arrhythmia or patient with heart failure.
Possible B2B documentation includes approved specifications, certificates of analysis and market-specific CTD/ACTD dossiers where available. A prolonged-release designation requires supporting dissolution and regulatory evidence.
WHO-GMP, COPP, Free Sale Certificate, Star Export House status, export destinations, shipping terms and packaging options must be verified from current records.
Q: Is the 40 mg product definitely prolonged-release?
A: The supplied brief calls it prolonged-release, but this unusual presentation requires confirmation against the approved label and release profile.
Q: Is the 80 mg tablet prolonged-release?
A: The supplied label identifies an 80 mg film-coated tablet only; it does not establish prolonged release.
Q: Can immediate-release and prolonged-release tablets be substituted?
A: Not without prescriber/pharmacist assessment; schedules and release characteristics differ.
Q: Are 120 mg and 240 mg confirmed products?
A: They appear in the general description but not the supplied product labels.
Dosing is determined by the prescriber based on the specific product, cardiovascular indication, heart rate, blood pressure, age, liver function and interacting medicines. Do not use a generic once-daily regimen for an unverified 40 mg prolonged-release formulation.
Modified-release tablets generally should not be crushed or chewed; follow the exact approved label for splitting or administration. Do not switch formulations without professional advice.
Seek urgent medical attention for fainting, very slow heartbeat, severe dizziness, shortness of breath or worsening chest pain.
Store in the original protective packaging according to the temperature and moisture conditions on the approved product label. A universal below-25°C requirement cannot be confirmed from the supplied text. Keep out of reach of children.
For healthcare professional and B2B reference. Product availability, approvals, certifications, manufacturing processes, packaging and prescribing details must be verified for the relevant market.